首页> 外国专利> Vaevsplasminoaktivator- (t-PA) variant with zymogenic or fibrin or plasma clot-specific properties, process for their preparation, DNA sequence encoding the variant, a replicable expression vector for this and host cells transformed with the vector

Vaevsplasminoaktivator- (t-PA) variant with zymogenic or fibrin or plasma clot-specific properties, process for their preparation, DNA sequence encoding the variant, a replicable expression vector for this and host cells transformed with the vector

机译:具有酶原性或纤维蛋白或血浆凝块特异性特性的Vaevsplasminoaktivator-(t-PA)变体,其制备过程,编码该变体的DNA序列,可复制的表达载体以及用该载体转化的宿主细胞

摘要

Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.
机译:制备组织纤溶酶原激活物(t-PA)酶原和变体,包括与相应的野生型t-相比,t-PA的纤溶活性变体,该变体在t-PA蛋白酶域内的位点具有氨基酸改变。与相应的野生型t-PA相比,PA的改变使得在存在纤溶酶降解的纤维蛋白原和/或纤维蛋白(或血浆凝块)的情况下,变体具有致酶性。可以制备编码酶原和变体的DNA序列,以及掺入DNA序列的表达载体,以及用表达载体转化的宿主细胞。酶原和变体可用于药物制剂中,以治疗血管疾病或病症或防止哺乳动物中血纤蛋白沉积或粘附形成或再形成。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号